AoFrio FY22 Record Revenue up 16% and 2023 Guidance
A: 21 Arrenway Drive, Rosedale, Auckland 0632, New
Zealand PO Box: 302-533 North Harbour, Auckland 0751,
New Zealand
P: + 64 9 477 4500 E: info@aofrio.com
® is a registered Trademark of AoFrio Ltd.
19 January 2023
Market Announcement
For immediate release
AoFrio FY22 Record Revenue up 16% and 2023 Guidance
AoFrio provides unaudited FY22 results and an update on FY23 budgets in the interests of keeping the
market informed following the conclusion of the financial year ending 31 December 2022 (FY22).
Invoicing in December 2022 was a record high for the Company at $10.7 million. After adjusting for the
deferral of revenue to be recognised in future periods, revenue for the three months to 31 December 2022
(Q4) was NZ$24.3 million and NZ$74.3 million for the 2022 year. This is a 16% increase compared to the
2021 year and a record annual revenue for the business.
NZ$000s 2022 2021 % Change
Q1 18.4 14.6 +26.0%
Q2 13.5 15.9 -15.1%
Q3 18.1 15.3 +18.3%
Q4 24.3 18.3 +32.8%
Full Year 74.3 64.2 +15.7%
Greg Balla, CEO of AoFrio, says: “Revenue was constrained by supply chain challenges for most of the
year. Component shortages meant we could not manufacture product for 6 weeks mid-year. The
performance in Q4 demonstrates how we reengineered our products and invested to navigate these supply
chain issues. We are now positioned to leverage market opportunities in 2023 and beyond.
“By the end of the financial year, the business achieved its largest December ever in terms of invoicing and a
record annual revenue in NZ$, assisted by US$ appreciation.
“IoT products grew by 47% to make up 50% of 2022 revenue, compared to 39% in 2021. December saw the
first significant sales of our new Network Pro always-on connected device to a major brand bottler, and of
our Connect Monitor battery operated device to a major consumer brand for an ice cream freezer
application.
“Revenue from motors declined 4% compared to FY21. This shift in balance between motors and IoT
revenue is reflective of the AoFrio’s strategy to grow IoT revenue, but it has also been impacted by supply
chain challenges within manufacturing,” says Balla.
EBITDA Impact of December Revenue
Although the performance in December was very strong, and factory production was at near capacity,
revenue was lower than previously forecast.
This was because of delays in customers signing off product specifications which impacted production for
the month, and the Company not being able to secure shipping space until early January for some orders.
This revenue will now be recognised in Q1 FY23.
There are also signs that some customers have higher inventory positions than usual due to over ordering as
a way to navigate global supply constraints. This extra inventory is expected to be consumed in Q1.
WT9727
A: 21 Arrenway Drive, Rosedale, Auckland 0632, New
Zealand PO Box: 302-533 North Harbour, Auckland 0751,
New Zealand
P: + 64 9 477 4500 E: info@aofrio.com
® is a registered Trademark of AoFrio Ltd.
The 2022 financial results are currently being finalised for audit. But lower than forecast revenue in
December is expected to deliver an EBITDA* result around $1.5 million.
FY23 Outlook
Operating plans and financial budget for 2023 has been approved by the directors. The business is
forecasting revenue growth exceeding 30% in FY23, trending AoFrio towards becoming a NZ$100 million
revenue company. EBITDA is expected to be around $3.5 million. The forecasts assume a US$ / NZ$ rate of
0.6445.
“Our 2023 business plan leverages our current product range (Connect SCS, ECR motors) to new
customers, as well as recently developed products (Network Pro and Connect Monitor) and new products
under development for existing and adjacent markets (bottle coolers, ice cream, food service, beer, medical).
“To achieve this revenue growth, we are investing in new product development and the addition of specialist
skilled people. Operating costs as a result increase by $6 million. The 2023 budget also includes capital
expenditure of $2.5 million. All investments will be funded out of operating cash flows,” says Balla.
The Company however remains cautious about its base demand, given elevated global macroeconomic
risks from rising interest rates that could slow global growth and impact future revenue, so will take a
measured approach to this investment until demand is confirmed by customers.
More detail on AoFrio’s strategies for growth and audited results will be provided in the Company’s Annual
Report to be released at the end of February 2023.
Authorised by:
Board of Directors of AoFrio Limited
Ends
*EBITDA (i.e., Earnings before interest, taxation, depreciation, amortisation, and impairment) is a non-GAAP
earnings figure that equity analysts tend to focus on for comparable company performance analysis. AoFrio
considers it a valuable financial indicator because it avoids the distortions caused by differences in
amortisation and impairment policies. Contact
Greg Balla Howard Milliner
Chief Executive Officer Chief Financial Officer
Phone + 64 21 938 601 +64 27 587 0455
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- AFT — AFT Pharmaceuticals Limited: 2023 New Year letter to investors2023-01-08
“AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com 9 January 2023 2023 New Year letter to investors AFT Pharmaceuticals (NZX: A…”
- AFT — AFT Pharmaceuticals Limited: AFT extends growth investment as sales surge2022-11-23
“AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com 24 NOVEMBER 2022 FINANCIAL RESULTS FOR THE SIX MONTHS TO 30…”
- FPH — Fisher & Paykel Healthcare Corporation Limited: FPH announces results for the first half of FY232022-11-28
“impacted by manufacturing inefficiencies, as it carefully balances demand fluctuations while managing manufacturing throughput and higher rates of sickness-related absenteeism in the manufacturing workforce. The company reached a number of infrastructure milestones over the…”